Reaction

Oral Fungal Infection reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,710 reports · 72 co-occurring drugs

As of the last recalculation, Oral Fungal Infection appears in 2,710 FAERS reports alongside 72 co-occurring drug terms. The strongest observed disproportionality signal is NYSTATIN OINTMENT (PRR 18.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Nystatin Ointment	62	18.6	18.6
Nystatin Cream	62	18.5	18.6
Nystatin	62	17.8	17.8
Polatuzumab Vedotin	22	17.4	17.5
Micafungin Sodium	18	16.4	16.4
Bendamustine Hydrochloride	23	14.9	14.9
Bimekizumab	38	13.9	13.9
Salmeterol Xinafoate	13	11.6	11.7
Methylprednisolone Acetate	12	11.6	11.6
Fluconazole	94	10.6	10.6
Obinutuzumab	22	10.3	10.4
Bendamustine Hcl	20	10.0	10.0
Anakinra	21	9.8	9.8
Desoximetasone	22	8.9	8.9
Fluticasone Propionate And Salmeterol	45	8.4	8.4
Quinine	9	8.1	8.1
Human Immunoglobulin G	20	7.5	7.5
Ciclesonide	13	7.4	7.4
Melphalan	21	7.1	7.1
Melphalan Hydrochloride	21	6.5	6.5
Vemurafenib	10	6.4	6.4
Ado-Trastuzumab Emtansine	7	6.4	6.4
Umeclidinium	7	6.0	6.0
Drs. Clotrimazole	9	6.0	6.0
Family Wellness Clotrimazole	9	6.0	6.0
Clotrimazole Topical	9	6.0	6.0
Pemetrexed Disodium	29	5.9	5.9
Fluticasone Propionate And Salmeterol Xinafoate	45	5.8	5.8
Niacin	8	5.3	5.3
Brentuximab Vedotin	7	5.3	5.3
Ixekizumab	25	5.2	5.2
Budesonide And Formoterol Fumarate Dihydrate	64	5.2	5.2
Fluticasone Furoate And Vilanterol Trifenatate	24	5.2	5.2
Budesonide, Glycopyrrolate, And Formoterol Fumarate	7	5.2	5.2
Filgrastim	25	5.1	5.1
Fexofenadine	11	5.1	5.1
Naproxen Sodium Tablet, Coated	9	5.1	5.1
Naproxen Sodium, Coated Tablets	9	5.1	5.1
Naproxen Sodium 220Mg	9	5.1	5.1
Pemetrexed	13	4.7	4.7
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	25	4.7	4.7
Thalidomide	21	4.4	4.4
Tiotropium Bromide	77	4.4	4.4
Secukinumab	88	4.3	4.3
Venetoclax	34	4.3	4.3
Umeclidinium Bromide And Vilanterol Trifenatate	9	4.1	4.1
Amikacin	9	4.1	4.1
Baricitinib	5	4.0	4.0
Atezolizumab	20	4.0	4.0
Regorafenib	6	4.0	4.0
Canagliflozin	15	3.9	3.9
Cisplatin	38	3.8	3.8
Deferasirox	12	3.5	3.5
Peginterferon Alfa-2A	23	3.3	3.3
Fexofenadine Hydrochloride	9	3.2	3.2
Doxorubicin	36	3.1	3.1
Ocrelizumab	25	3.1	3.1
Lapatinib	6	3.0	3.0
Mometasone Furoate And Formoterol Fumarate Dihydrate	6	3.0	3.0
Sunitinib Malate	15	2.9	2.9
Ribavirin	23	2.8	2.8
Cabozantinib	17	2.7	2.7
Abemaciclib	7	2.7	2.7
Selinexor	3	2.7	2.7
Nivolumab	33	2.6	2.6
Rucaparib	3	2.6	2.6
Certolizumab Pegol	38	2.5	2.5
Cetuximab	10	2.5	2.5
Ipilimumab	13	2.3	2.3
Remdesivir	4	2.3	2.3
Durvalumab	6	2.3	2.3
Alirocumab	7	2.1	2.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.